Agree. It's good to see management making even nominal investments in a company. I doing think it implies anything specifically with the AD Part B results, but it shows Missling still sees potential in the pipeline, though that is not surprising. There is a lot of pre-clinical research showing that 2-73 and 3-71 should/might be therapeutic for something. Time (aka robust sustained results and new clinical trials) will tell.